Home › Forums › Main Forum › Experts Corner › Velpatasvir is not suitable for home compounding from API
- This topic has 10 replies, 7 voices, and was last updated 8 years, 7 months ago by
Dr James.
-
AuthorPosts
-
30 June 2016 at 3:17 pm #20183
Hmmm … so I’m guessing somebody in Bangladesh is about to win a race to market again. My money is on Incepta.
Edit: I asked this on another thread, but it actually belongs here ….
Is the compounding process for Velpatasvir something which can be done by any compounding chemist, i.e., Kingswood?
30 June 2016 at 3:54 pm #20186So…..
Does Mesochem ledipasvir need to be ground or has it been chemically altered to allow absorbtion as purchased?
I really, really hope its the latter….
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2430 June 2016 at 7:41 pm #20194One of the leading generic manufactures in India has an internal meeting July 17th on Velpatasvir. This will go through similar process as Sof and Sof+Led
1. Extensive licensing with patenting company(already done). Estimated number of companies to sell the licensed product is 11
2. Drug Controller General of India(DCGI) approval.Current estimates are its going to take longer than 1 month.
We will know more post the July 17th meeting.
1 July 2016 at 2:24 am #20203Solubility is relative. Compared to Velpatasvir Ledipasvir is soluble enough under acid conditions to have a lot more wiggle room and real world SVR rates of 93.4% overall are solidly in line with expectations.
YMMV
1 July 2016 at 2:54 am #20209Regarding simeprevir ..
It is my understanding that Janssen uses simeprevir sodium in their branded Olysio, Sovriad and Galexos capsules. The simeprevir API currently available from China is not the sodium salt and therefor of questionable use.
The linked disclosure of a cardiotoxic impurity (Related Substance C) present in the simeprevir manufacturing process poses a greater complexity.
From my reading – Johnson & Johnson (Janssen) has been seeing a substantial decrease in demand for this medicine. Aside from the recommended use in retreatment – is there a market for simeprevir based medicines sufficient to warrant the development of a generic ??
Certainly J&J has studied this ad nauseam – curious to know what folks here are seeing in the real world.
J
PS: Note that simeprevir (Olysio) is part of my upcoming retreatment plan. Current retail price here in the States is $22,500 USD for 28 capsules (150 mg). 24 weeks makes for $135,000 for this component alone. Outrageous ..
GT 1a (~196
Diagnosed Non A/B ’85 – HCV ‘89
Rebetron INF/RBV 17 months 2000 – Failure
Infergen INF/RBV 11 months 2002 – Failure
Viekira Pak + RBV 12 weeks 2015 – Failure
VL Und at +3 weeks > EOT – EOT+12 weeks 2,240k
Resistance Tests – NS5a Q30R
SMV/DCV/SOF + RBV 24 weeks 2016
VL Det <15 +2 and +4 weeks – Und +8 weeks > EOT
SVR4, SVR12 and SVR24 Undetected1 July 2016 at 3:33 am #20217It is outrageous!
And yes, the Mesochem simeprevir is not absorbable.
m
Curehcvnow@gmail.com
http://forums.delphiforums.com/generichcvtxG 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 2420 September 2016 at 1:11 am #23131Hello!
Could someone possibly share information regarding the India launch and what’s the state of affairs?
Gen 1b
VL pre treatment 29000 ME/ml
AST 32 ALT 94, F0
Started treatment 13 January 2017
Generic sofosbuvir/velpatasvir (Incepta)
VL 9 days into treatment <300 (undetected)
AST 13.8 ALT 22
Side effects: mild dehydration, not a problem at all if I drink water at night, nothing to worry about
Diet and gastric ph are very important with velpatasvir. One must think what and when to eat to keep gastric pH low. Side effects disappeared 2 weeks after, unless I ate anything < 4hrs before the pill. SVR60.20 September 2016 at 8:32 am #23147It’s really anyones guess:
Accelerated stability testing and then DCGI approval both need to be navigated before it hits the market. There may be other contractural restrictions that are delaying it. There was not a lot of logical reason for the > 6 month delay between generic Sovaldi and generic Harvoni (given both had been FDA approved, tech transfer done, etc.
YMMV
27 September 2016 at 12:36 pm #23296MonkMed wrote:One of the leading generic manufactures in India has an internal meeting July 17th on Velpatasvir. This will go through similar process as Sof and Sof+Led
1. Extensive licensing with patenting company(already done). Estimated number of companies to sell the licensed product is 11
2. Drug Controller General of India(DCGI) approval.Current estimates are its going to take longer than 1 month.
We will know more post the July 17th meeting.
Can anyone update me about Velpatasvir’s availability? Did a search on this site but if this info is there, I did not find it.
Just curious mind you.
J.
27 September 2016 at 6:56 pm #23302 -
AuthorPosts
- You must be logged in to reply to this topic.